Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland

Reuters08-13

Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland

Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2559604979?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-13 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2559604979","market":"fut","top_or_hot":-1,"title":"Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-13 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYNZ","symbol_name":"Mainz Biomed B.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL2XFlYt:1","article_id":"2559604979","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2559604979","pubTimestamp":1755086628,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYNZ":"Mainz Biomed B.V.","BK4139":"生物科技"},"translate_title":"Mainz Biomed NV的ColoAlert获得Swissmedic批准®瑞士的癌症筛查测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYNZ":0.9},"content_text":"Mainz Biomed NV Receives Swissmedic Approval for ColoAlert® Cancer Screening Test in Switzerland\n    \n\n        Mainz Biomed NV, a diagnostics company specializing in cancer early detection, has announced that its non-invasive colorectal cancer screening test, ColoAlert®, has been officially registered and granted marketing approval by Swissmedic, the Swiss agency for therapeutic products. This approval allows ColoAlert to be marketed in Switzerland, following a partnership with the Swiss diagnostic laboratory, labor team w ag. The test, which detects colorectal cancer tumor DNA and other biomarkers in stool samples with high sensitivity, aims to improve early detection and increase participation in screening programs in Switzerland, where less than half of the eligible population currently participates in such programs. This milestone is part of Mainz Biomed's broader strategy to expand access to reliable colorectal cancer early detection solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2182912_de), on August 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2559604979","isCrawlerRequest":true}